Sepsis/acute respiratory distress syndrome

Clinics in Family Practice

Volumn 6, Issue 1, 2004, Pages 101-126

  Udobi, Kahdi F ^a   Childs, Ed W ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b Texas A/M Univ Sys Hlth Sci Ctr   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; BRADYKININ ANTAGONIST; CASPOFUNGIN; CEFEPIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; CYTOKINE; DALFOPRISTIN PLUS QUINUPRISTIN; DOPAMINE; DROTRECOGIN; FLUCONAZOLE; HUMAN MONOCLONAL ANTIBODY; INTERLEUKIN 1 ANTIBODY; LEVOFLOXACIN; LINEZOLID; LIPOPOLYSACCHARIDE; MEROPENEM; MINERALOCORTICOID; NITRIC OXIDE; PEPTIDOGLYCAN; PHENYLEPHRINE; PIPERACILLIN PLUS TAZOBACTAM; PROTEIN C; REACTIVE OXYGEN METABOLITE; UNINDEXED DRUG; VANCOMYCIN; VASOPRESSIN;

ACUTE DISEASE; ACUTE PANCREATITIS; ADRENAL INSUFFICIENCY; ANTIBIOTIC RESISTANCE; ANTICOAGULATION; ARTIFICIAL VENTILATION; BLEEDING; BLOOD PRESSURE MONITORING; CLINICAL FEATURE; CLINICAL TRIAL; DIABETIC KETOACIDOSIS; DIFFERENTIAL DIAGNOSIS; DRUG FATALITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEART CATHETERIZATION; HUMAN; HYPOTENSION; IMAGING SYSTEM; LABORATORY TEST; LUNG EMBOLISM; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PREVALENCE; RESPIRATORY DISTRESS SYNDROME; REVIEW; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOXIC SHOCK SYNDROME;

EID: 1542574987     PISSN: 15225720     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cfp.2003.12.001     Document Type: Review

References (98)

1. Martin G.S. Mannino D.M. Eaton S. Moss M. The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 348 2003 1546-1554
2. Bone R. Balk R. Cerra F. Dellinger P. Fein A. Knaus W. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis Crit Care Med 20 1992 864-874
3. Sands K. Bates D. Lanken P. Graman P. Hibberd P. Kahn K. Epidemiology of sepsis syndrome in 8 academic medical centers JAMA 278 1997 234-240
4. Angus D. Linde-Zwirble W. Lidlicker J. Clermont G. Carcillo J. Pinsky M. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care Crit Care Med 29 2001 1303-1310
5. Brun-Buisson C. Doyon F. Carlet J. Dellamonica P. Gouin F. Lepoutre A. et al. Incidence, risk factors and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units JAMA 274 1995 968-974
6. Wichmann M.W. Inthorn D. Andress H.J. Schildberg F.W. Incidence and mortality of severe sepsis in surgical intensive care patients: the influence of patient gender on disease process and outcome Intensive Care Med 26 2000 167-172
7. Centers for Disease Control Mortality patterns - United States MMWR 41 1989 121-125
8. Bone R.C. Toward an epidemiology and natural history of SIRS JAMA 268 1992 3452-3455
9. Angele M.K. Ayala A. Monfils B.A. Cioffi W.G. Bland K.I. Chaudry I.H. Testosterone and/or low estradiol: normally required but harmful immunologically for males after trauma-hemorrhage J Trauma 44 1998 78-84
10. Schroder J. Kahlke V. Staubach K. Zabel P. Stuber F. Gender differences in human sepsis Arch Surg 133 1998 1200-1205
11. Eachempati S. Hydo L. Barie P. Gender-based differences in outcome in patients with severe sepsis Arch Surg 134 1999 1342-1347
12. Mclaughlin G.J. Anderson I.D. Grant I.S. Fearon K.C. Outcome of patients with abdominal sepsis treated in an intensive care unit Br J Surg 82 1995 524-529
13. Thyrault M. Gachot B. Chastang C. Souweine B. Timsit J.F. Bedos J.P. et al. Septic shock in patients with the acquired immunodeficiency syndrome Intensive Care Med 23 1997 1018-1023
14. Moss M. Burnham E.L. Chronic alcohol abuse, acute respiratory distress syndrome and multiple organ dysfunction Crit Care Med 31 2003 S207-S212
15. Flores J.M. Jimenez P.I. Rincon M.D. Marquez J.A. Navarro H. Arteta D. et al. Early risk factors for sepsis in patients with severe blunt trauma Injury 32 2001 5-12
16. Cumming J. Purdue G.F. Hunt J.L. Okeefe G.E. Objective estimates of the incidence and consequences of multiple organ dysfunction and sepsis after burn trauma J Trauma 50 2001 510-515
17. Fitzwater J. Purdue G.F. Hunt J.L. Okeefe G.E. The risk factors and time course of sepsis and organ dysfunction after burn trauma J Trauma 54 2003 959-966
18. Yan S.B. Helterbrand J.D. Hartman D.L. Bernard G.R. Low levels of protein C are associated with poor outcome in severe sepsis Chest 120 2001 915-922
19. Harbath S. Holeckova K. Froidevaux C. Pittet D. Ricou B. Grau G.E. et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis Am J Respir Crit Care Med 164 2001 396-402
20. Luzanni A. Polati E. Dorizzi R. Rungatscher A. Pavan R. Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis Crit Care Med 31 2003 1737-1741
21. Hollenberg S.M. Parillo J.E. Shock In Fauci A.S. Braunwald E. Isselbacher K.J. et al. (Eds.), Harrison's principles of internal medicine 1997 214-222 McGraw-Hill New York
22. Kumar A. Haery C. Parillo J.E. Myocardial depression in septic shock Crit Care Clin 16 2002 251-287
23. Rangel-Frausto M.S. Pittet D. Costigan M. Hwang T. Davis C.S. Wenzel R.P. The natural history of the systemic inflammatory response syndrome (SIRS) JAMA 273 1995 117-123
24. Reyes W.J. Brimioulle S. Vincent J.L. Septic shock without documented infection: an uncommon entity with a high mortality Intensive Care Med 25 1999 1267-1270
25. Opal S.M. Cohen J. Clinical gram-positive sepsis: does it differ fundamentally from gram-negative bacterial sepsis? Crit Care Med 27 1999 1608-1616
26. Tudor G.R. Finlay D.B. Belton I. The value of indium-111-labelled leucocyte imaging and ultrasonography in the investigation of pyrexia of unknown origin Br J Radiol 70 1997 918-922
27. Minoja G. Chiaranda M. Fachinetti A. Raso M. Dominioni L. Torre D. et al. The clinical use of 99m-Tc-labeled WBC scintigraphy in critically ill surgical and trauma patients with occult sepsis Intensive Care Med 22 1996 867-871
28. McLauchlan G.J. Anderson I.D. Grant I.S. Fearon K.C. Outcome of patients with abdominal sepsis treated in an intensive care unit Br J Surg 82 1995 524-529
29. Cooper G.S. Shlaes D.M. Salata R.A. Intraabdominal infection: differences in presentation and outcome between younger patients and the elderly Clin Inf Dis 146 1994 146-148
30. Podnos Y.D. Jimenez J.C. Wilson S.E. Intra-abdominal sepsis in elderly persons Clin Inf Dis 35 2002 62-68
31. Hotchkiss R.S. Karl I.E. The pathophysiology and treatment of sepsis N Engl J Med 348 2003 138-150
32. Task force of the American College of Critical Care Medicine Society of Critical Care Medicine Practice parameters for hemodynamic support of sepsis in adult patients in sepsis Crit Care Med 27 1999 639-660
33. Landry D.W. Levin H.R. Gallant E.M. Ashton R.C. Seo S. D'Alessandro S. et al. Vasopressin deficiency contributes to the vasodilation of septic shock Circulation 95 1997 1122-1125
34. Holmes C.L. Patel B.M. Russell J.A. Walley K.R. Physiology of vasopressin relevant to management of septic shock Chest 120 2001 989-1002
35. Sharshar T. Blanchard A. Paillard M. Raphael J.C. Gajdos P. Annane D. Circulating vasopressin levels during septic shock Crit Care Med 32 2003 1752-1758
36. Landry D.W. Levin H.R. Gallant E.M. Seo S. D'Alessandro S. Os M.C. et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock Crit Care Med 25 1997 1279-1282
37. Malay B. Ashton R.C. Landry D.W. Townsend R.N. Low-dose vasopressin in the treatment of vasodilatory septic shock J Trauma 47 1999 703-705
38. Anzueto A.E. Gutierrez G. Tessler S. San Pedro G. Wunderink R. Dal Nagore A. et al. Double-blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock Lancet 351 1998 929-933
39. Fisher C.J. Slotman G.J. Opal S.M. Pribble J.P. Bone R.C. Emmanuel G. et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open label placebo-controlled multicenter trial Crit Care Med 22 1994 12-21
40. Opal S.M. Fisher C.J. Dhainaut J.F. Vincent J.L. Brase R. Lowry S.F. et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, double-blind placebo-controlled multicenter trial Crit Care Med 25 1997 115-124
41. Dhainaut J.F. Tenaillon A. Le Tulzo Y. Schlemmer B. Solet J.P. Wolff M. et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind placebo-controlled multicenter clinical trial. BN 52021 Sepsis Study Group Crit Care Med 22 1994 1720-1728
42. Dhainaut J.F. Tenaillon A. Hemmer M. Damas P. Le Tulzo Y. Radermacher P. et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a randomized, double-blind placebo-controlled multicenter clinical trial. BN 52021 Sepsis Investigator Group Crit Care Med 26 1998 1963-1971
43. Fein A.M. Bernard G.R. Criner G.J. Fletcher E.C. Good J.T. Knaus W.A. et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127) JAMA 277 1997 842-847
44. Albertson T.E. Panacek E.A. MacArthur R.D. Johnson S.B. Benjamin E. Matuschak G.M. et al. Multicenter evaluation of a human monoclonal antibody to Enterobacteriacea common antigen in patients with gram-negative sepsis Crit Care Med 31 2003 419-427
45. Bernard G.R. Vincent J.L. Laterre P.F. LaRosa S.P. Dhainaut J. Lopez-Rodriguez A. Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 2001 699-709
46. Sollet J. Garber G.E. Selecting patients with severe sepsis for drotrecognin alfa (activated) therapy Am J Surg 184 2002 11S-18S
47. Morris P.E. Light R.B. Garber G.E. Identifying patients who should not be treated with drotrecognin alfa (activated) Am J Surg 184 2002 19S-24S
48. Maki D.G. Conclusions: drotrecognin alfa (activated)-from bench to practical use at the bedside Am J Surg 184 2002 47S-49S
49. Schumer W. Steroids in the treatment of clinical septic shock Ann Surg 184 1976 333-339
50. Cronin L. Cook D.J. Carlet J. Heyland D.K. King D. Lansang M.A. et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature Crit Care Med 23 1995 1430-1439
51. Meduri G.U. Headley S. Golden E. Carson S.J. Umberger R.A. Kelso T. et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome JAMA 280 1998 159-165
52. Bollaert P.E. Charpentier C. Levy B. Debouverie M. Audibert G. Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone Crit Care Med 26 1998 645-660
53. Briegel J. Forst H. Haller M. Schelling G. Kilger E. Kuprat G. et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective randomized, double-blind, single center study Crit Care Med 27 1999 723-732
54. Annane D. Sebilli V. Troche G. Raphael J. Gajdos P. Bellisant E. et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotrophin JAMA 283 2002 1038-1045
55. Annane D. Sebilli V. Charpentier C. Bollaert P. Francois B. Korach J. et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock JAMA 288 2000 862-871
56. Sessler C.N. Steroids for septic shock. Back from the dead? (Con) Chest 123 2003 482S-489S
57. Balk R.A. Steroids for septic shock. Back from the dead? (Pro) Chest 123 2003 490S-499S
58. Bone R. Fisher C.J. Clemmer T.P. Slotman G.J. Metz C.A. Balk R.A. Sepsis syndrome: a valid entity. Methylprednisolone study group Crit Care Med 17 1989 389-393
59. Danner R.L. Elin R.J. Hosseini J.M. Wesley R.A. Reilly J.M. Parillo J.E. Endotoxemia in human septic shock Chest 99 1991 169-175
60. Hudson L.D. Milberg J.A. Anardi D. Maunder R.J. Clinical risks for development of the acute respiratory distress syndrome Am J Respir Crit Care Med 151 1995 293-301
61. Fein A.M. Calalang-colucci M.G. Acute lung injury and acute respiratory distress syndrome Crit Care Clin 16 2000 289-317
62. Humprey H. Hall J. Sznajder I. Silverstein M. Wood L. Improved survival in ARDS patients associated with a reduction in the pulmonary capillary wedge pressure Chest 97 1990 1176-1180
63. Mitchell J.P. Schuller D. Calandrino F.S. Schuster D.P. Improved outcome based on fluid management in the critically ill patients requiring pulmonary artery catheterization Am Rev Respir Dis 145 1992 990-998
64. Gadek J.E. DeMichele S.J. Karlstad M.D. Pacht E.R. Donahoe M. Albertson T.E. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome Crit Care Med 27 1999 1409-1420
65. Dreyfuss D. Saumon G. Ventilator-induced lung injury: lessons from experimental studies Am J Respir Crit Care Med 157 1998 294-323
66. International consensus conference in intensive care medicine: ventilator-associated lung injury in ARDS Am J Respir Crit Care Med 160 1999 2118-2124
67. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome N Engl J Med 342 2000 1301-1308
68. Jepsen S. Herlevson P. Knudsen P. Bud M.I. Klausen N.O. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized placebo-controlled study Crit Care Med 20 1992 918-923
69. Anzueto A. Baughman R.P. Guntupalli K.K. Weg J.G. Weidemann H.P. Raventos A.A. et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome N Engl J Med 334 1996 1417-1421
70. Hirschl R.B. Croce M. Gore D. Wiedman H. Davis K. Zwischenberger J. et al. Prospective randomized controlled pilot study of partial liquid ventilation in adult acute respiratory distress syndrome Am J Respir Crit Care Med 165 2002 781-787
71. Eggiman P. Harbath S. Ricou B. Hugonnet S. Ferriere K. Suter P. et al. Acute respiratory distress syndrome after bacteremic sepsis does not increase mortality Am J Respir Crit Care Med 167 2003 1210-1214
72. Simon D. Trenholme G. Antibiotic selection for patients with septic shock Crit Care Clin 16 2000 215-231
73. Todd J. Fishaut M. Kapral F. Welch T. Toxic shock syndrome associated with phage group-1 staphylococci Lancet 2 1978 1116-1118
74. Centers for Disease Control Follow-up on toxic shock syndrome-United States MMWR 29 1980 297-299
75. Manders S.M. Toxin-mediated streptococcal and staphylococcal disease J Am Acad Dermatol 39 1998 383-398
76. Greenman R.L. Immerman R.P. Toxic shock syndrome: what have we learned? Postgrad Med 81 1987 147-160
77. Issa N.C. Thompson R.L. Staphylococcal toxic shock syndrome Postgrad Med 110 2001 55-62
78. Shands K.N. Schmid G.P. Dan B.B. Blum D. Guidotti R.J. Hargrett N.T. Toxic-shock in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases N Engl J Med 303 1980 1436-1442
79. Strausbaugh L.J. Toxic shock syndrome. Are you recognizing its changing presentations? Postgrad Med 94 1993 107-118
80. Hajjeh R.A. Reingold A. Weil A. Shutt K. Schuchat A. Perkins B.A. Toxic shock syndrome in the United States: surveillance update, 1979 1996 Emerg Infect Dis 5 1999 807-810
81. Dellinger R.P. Cardiovascular management of septic shock Crit Care Med 31 2003 946-955
82. Friedman G. Silva E. Vincent J.L. Has the mortality of septic shock changed with time? Crit Care Med 26 1998 2078-2086
83. Knaus W.A. Draper E.A. Wagner D.P. Zimmerman J.E. Prognosis in acute organ-system failure Ann Surg 202 1985 685-693
84. Astiz M.E. Rackow E.C. Septic shock Lancet 351 1998 1501-1505
85. Sasse K.C. Nauennberg E. Long A. Anton B. Tucker H.J. Hu T. Long-term survival after intensive care unit admission with sepsis Crit Care Med 23 1995 1040-1047
86. Quartain A.A. Scein R.M. Kett D.H. Peduzzi P.N. Magnitude and duration of the effect of sepsis on survival JAMA 277 1997 1053-1063
87. Heyland D.K. Hopman W. Coo H. Tranmer J. McColl M. Long-term health related quality of life in survivors of sepsis. Short form 36: a valid and reliable measure of health related quality of life Crit Care Med 28 2000 3599-3605
88. Perl T.M. Dvorak L. Hwang T. Wenzel R.P. Long-term survival and function after suspected gram-negative sepsis JAMA 274 1995 338-345
89. Davidson T.A. Caldwell E.S. Curtis J.R. Hudson L.D. Steinberg K.P. Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients JAMA 281 1999 354-360
90. Weinert C.R. Gross C.R. Kangas J.R. Bury C.L. Marinelli W.A. Health-related quality of life after acute lung injury Am J Respir Crit Care Med 156 1997 1120-1128
91. Oberholzer C. Oberholzer A. Care-Salzler M. Moldawer L.L. Apoptosis in sepsis: a new target for therapeutic exploration FASEB 15 2001 879-892
92. Hotchkiss R.S. Swanson P.E. Freeman B.D. Tinsley K.W. Cobb J.P. Matuschak G.M. et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction Crit Care Med 27 1999 1230-1248
93. Hotchkiss R.S. Swanson P.E. Knudson C.M. Chang K.C. Cobb J.P. Osborne D.F. et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis J Immunol 162 1999 4148-4156
94. Reidemann N.C. Guo R.F. Neff T.A. Laudes I.J. Keller K.A. Sarma V.J. et al. Increased C5a receptor expression in sepsis J Clin Invest 110 2002 101-108
95. Czermak B.J. Sarma V. Pierson C.L. Warner R.L. Huber-Lang M. Protective effects of C5 a blockade in sepsis Nat Med 5 1999 788-792
96. Calandra T. Echtenacher B. Roy D.L. Pugin J. Metz C.N. Hultner L. et al. Protection from septic shock by neutralization of macrophage migration inhibition factor Nat Med 6 2000 164-170
97. Andersson U. Wang H. Palmblad K. Aveberger A.C. Bloom O. Erlandsson-Harris H. et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes J Exp Med 192 2000 565-570
98. Ulloa L. Ochani M. Yang H. Tanovic M. Halperin D. Yang R. et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation Proc Natl Acad Sci USA 99 2002 12351-12356